BTIG Research Lowers Aldeyra Therapeutics (NASDAQ:ALDX) Price Target to $9.00
Aldeyra Therapeutics (NASDAQ:ALDX – Free Report) had its price target lowered by BTIG Research from $11.00 to $9.00 in a report released on Monday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics […]
Aldeyra Therapeutics (NASDAQ:ALDX – Free Report) had its price target lowered by BTIG Research from $11.00 to $9.00 in a report released on Monday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics […]
